freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation aav gene therapy platform developed by amit nathwani, professor of haematology at ucl and cso of freeline therapeutics http://www.freelinetx.com
Company profile
Ticker
FRLN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Freeline Therapeutics Holdings Ltd
SEC CIK
FRLN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
1 Mar 24
EFFECT
Notice of effectiveness
26 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Feb 24
POS AM
Prospectus update (post-effective amendment)
22 Feb 24
SC 13E3/A
Going private transaction (amended)
20 Feb 24
25-NSE
Exchange delisting
20 Feb 24
6-K
Acquisition of Freeline by Syncona Becomes Effective
20 Feb 24
Latest ownership filings
SC 13D/A
Syncona Portfolio Ltd
22 Feb 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
12 Feb 24
SC 13G/A
Tetragon Financial Management LP
31 Jan 24
SC 13D/A
Syncona Portfolio Ltd
24 Nov 23
SC 13D/A
Syncona Portfolio Ltd
18 Oct 23
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
17 Jul 23
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 23
SC 13G/A
CHI Advisors LLC
13 Feb 23
SC 13G/A
Tetragon Financial Management LP
31 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.61 mm | 48.61 mm | 48.61 mm | |||
Cash burn (monthly) | 23.49 mm | 7.58 mm | 6.62 mm | |||
Cash used (since last report) | 350.92 mm | 113.20 mm | 98.87 mm | |||
Cash remaining | -302.32 mm | -64.59 mm | -50.27 mm | |||
Runway (months of cash) | -12.9 | -8.5 | -7.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.25 bn |
Total shares | 4.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tetragon Financial Management | 4.00 mm | $0.00 |
Polygon Management | 266.67 k | $688.00 mm |
Tang Capital Management | 100.00 k | $258.00 mm |
MS Morgan Stanley | 34.86 k | $89.94 mm |
UBS UBS Group AG - Registered Shares | 33.33 k | $86.00 mm |
Renaissance Technologies | 21.86 k | $56.00 k |
CHI Advisors | 21.67 k | $55.90 mm |
NTRS Northern Trust | 15.66 k | $40.40 mm |
Harbor Capital Advisors | 10.71 k | $27.63 mm |
Acadian Asset Management | 1.80 k | $4.00 k |
Press releases
Freeline Shareholders Approve Acquisition by Syncona
12 Feb 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX
27 Jan 24
FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
26 Jan 24